WO2008008539A3 - Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor - Google Patents

Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor Download PDF

Info

Publication number
WO2008008539A3
WO2008008539A3 PCT/US2007/016068 US2007016068W WO2008008539A3 WO 2008008539 A3 WO2008008539 A3 WO 2008008539A3 US 2007016068 W US2007016068 W US 2007016068W WO 2008008539 A3 WO2008008539 A3 WO 2008008539A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
growth factor
factor receptor
hepatocyte growth
fused heterocyclic
Prior art date
Application number
PCT/US2007/016068
Other languages
French (fr)
Other versions
WO2008008539A2 (en
Inventor
Brian Albrecht
David Bauer
Steven Bellon
Christiane Bode
Shon Booker
Alessandro Boezio
Deborah Choquette
Amico Derin D
Jean-Christophe Harmange
Satoko Hirai
Randall Hungate
Tae-Seong Kim
Richard Lewis
Longbin Liu
Julia Lohman
Mark Norman
Michele Potashman
Aaron Siegmund
Stephanie Springer
Markian Stec
Ning Xi
Kevin Yang
Original Assignee
Amgen Inc
Brian Albrecht
David Bauer
Steven Bellon
Christiane Bode
Shon Booker
Alessandro Boezio
Deborah Choquette
Amico Derin D
Jean-Christophe Harmange
Satoko Hirai
Randall Hungate
Tae-Seong Kim
Richard Lewis
Longbin Liu
Julia Lohman
Mark Norman
Michele Potashman
Aaron Siegmund
Stephanie Springer
Markian Stec
Ning Xi
Kevin Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008008539(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP07810473.4A priority Critical patent/EP2081931B1/en
Priority to BRPI0714387-7A priority patent/BRPI0714387A2/en
Priority to EA200900178A priority patent/EA016028B1/en
Priority to DK07810473.4T priority patent/DK2081931T3/en
Priority to CA002657327A priority patent/CA2657327A1/en
Priority to NZ574002A priority patent/NZ574002A/en
Priority to CN200780034205XA priority patent/CN101528743B/en
Priority to AU2007272783A priority patent/AU2007272783B2/en
Priority to MX2009000531A priority patent/MX2009000531A/en
Priority to ES07810473.4T priority patent/ES2592888T3/en
Application filed by Amgen Inc, Brian Albrecht, David Bauer, Steven Bellon, Christiane Bode, Shon Booker, Alessandro Boezio, Deborah Choquette, Amico Derin D, Jean-Christophe Harmange, Satoko Hirai, Randall Hungate, Tae-Seong Kim, Richard Lewis, Longbin Liu, Julia Lohman, Mark Norman, Michele Potashman, Aaron Siegmund, Stephanie Springer, Markian Stec, Ning Xi, Kevin Yang filed Critical Amgen Inc
Priority to KR1020097003060A priority patent/KR101140474B1/en
Priority to JP2009519563A priority patent/JP5532398B2/en
Publication of WO2008008539A2 publication Critical patent/WO2008008539A2/en
Priority to IL196243A priority patent/IL196243A/en
Publication of WO2008008539A3 publication Critical patent/WO2008008539A3/en
Priority to NO20090723A priority patent/NO20090723L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
PCT/US2007/016068 2006-07-14 2007-07-13 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor WO2008008539A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2009519563A JP5532398B2 (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives and methods of use thereof
ES07810473.4T ES2592888T3 (en) 2006-07-14 2007-07-13 [1,2,4] triazolo [4,3-a] pyridine derivatives useful as hepatocyte growth factor receptor inhibitors
MX2009000531A MX2009000531A (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives and methods of use.
DK07810473.4T DK2081931T3 (en) 2006-07-14 2007-07-13 [1,2,4] triazolo [4,3-a] pyridine derivatives which are useful as inhibitors of the hepatocyte growth factor receptor
BRPI0714387-7A BRPI0714387A2 (en) 2006-07-14 2007-07-13 compound, pharmaceutical composition, and methods for treating cancer, reducing tumor size, treating hgf-mediated disorders, and reducing metastasis in a tumor in a patient
NZ574002A NZ574002A (en) 2006-07-14 2007-07-13 [1,2,4]Triazolo[4,3-a]pyridine derivatives
CN200780034205XA CN101528743B (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives and methods of use
EP07810473.4A EP2081931B1 (en) 2006-07-14 2007-07-13 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor
EA200900178A EA016028B1 (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives and use thereof
CA002657327A CA2657327A1 (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives and methods of use
AU2007272783A AU2007272783B2 (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives and methods of use
KR1020097003060A KR101140474B1 (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
IL196243A IL196243A (en) 2006-07-14 2008-12-28 [1,2,4]triazolo[4,3-a]pyridine derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer
NO20090723A NO20090723L (en) 2006-07-14 2009-02-13 Condensed heterocyclic derivatives and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83088206P 2006-07-14 2006-07-14
US60/830,882 2006-07-14

Publications (2)

Publication Number Publication Date
WO2008008539A2 WO2008008539A2 (en) 2008-01-17
WO2008008539A3 true WO2008008539A3 (en) 2009-02-12

Family

ID=38800918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016068 WO2008008539A2 (en) 2006-07-14 2007-07-13 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor

Country Status (24)

Country Link
US (1) US8212041B2 (en)
EP (3) EP2081931B1 (en)
JP (1) JP5532398B2 (en)
KR (2) KR101140474B1 (en)
CN (1) CN101528743B (en)
AR (1) AR062056A1 (en)
AU (1) AU2007272783B2 (en)
BR (1) BRPI0714387A2 (en)
CA (1) CA2657327A1 (en)
CL (1) CL2007002062A1 (en)
CR (1) CR10614A (en)
DK (1) DK2081931T3 (en)
EA (1) EA016028B1 (en)
ES (1) ES2592888T3 (en)
IL (1) IL196243A (en)
MX (1) MX2009000531A (en)
MY (1) MY167135A (en)
NO (2) NO20090723L (en)
NZ (1) NZ574002A (en)
PE (2) PE20121506A1 (en)
TW (1) TWI394755B (en)
UA (1) UA95965C2 (en)
WO (1) WO2008008539A2 (en)
ZA (1) ZA200900662B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02736B (en) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
AR059898A1 (en) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS
PE20121506A1 (en) 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
US7727978B2 (en) * 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101506147B (en) 2006-09-07 2012-03-21 霍夫曼-拉罗奇有限公司 A process for the manufacture of snac (n-(8-[2-hydroxybenzoyl]-amino) salcaprozate sodium)
EP2068869A4 (en) 2006-10-06 2011-05-25 Abbott Lab Novel imidazothiazoles and imidazoxazoles
EA016527B1 (en) * 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Triazolopyridazine protein kinase modulators
HUE026659T2 (en) 2006-11-22 2016-07-28 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
EP2170337A4 (en) * 2007-06-28 2013-12-18 Abbvie Inc Novel triazolopyridazines
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.
FR2919870B1 (en) * 2007-08-09 2014-05-16 Sanofi Aventis NOVEL 6-TRIAZOLOPYRIDAZINE-SULFANYL BENZOTHIAZOLE AND BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PROCESS, PHARMACEUTICAL COMPOSITIONS, AND NOVEL USE AS CMET INHIBITORS
DE102007038957A1 (en) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-thioxo-pyridazine derivatives
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
BRPI0816767B8 (en) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa compound 4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-disubstituted 1',3'-ones, pharmaceutical composition and use of same
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
DE102007061963A1 (en) * 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
WO2009081970A1 (en) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Process for production of heterocycle-substituted pyridine derivative
EP2265614A1 (en) * 2008-02-28 2010-12-29 Novartis AG Imidazo [1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
SI2300455T1 (en) 2008-05-21 2017-12-29 Incyte Holdings Corporation Salts of 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)- imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide and processes related to preparing the same
MX2010012528A (en) * 2008-05-22 2010-12-02 Amgen Inc Heterocycles as protein kinase inhibitors.
DE102008028905A1 (en) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
BRPI0909945A2 (en) 2008-06-20 2015-07-28 Genentech Inc "compound, pharmaceutical composition, method for treating or alleviating the severity of a disease or condition responsive to inhibition of jak2 kinase activity in a patient, kit for treating a disease or disorder responsive to inhibition of jak kinase"
WO2009155551A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
DE102008037790A1 (en) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
ES2439291T3 (en) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. 3-Azabicyclo [3.1.0] hexyl derivatives as modulators of metabotropic glutamate receptors
TWI491610B (en) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP2346505B1 (en) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
PE20131197A1 (en) 2008-10-31 2013-11-06 Genentech Inc PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
DE102008063667A1 (en) 2008-12-18 2010-07-01 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
AU2009331990B2 (en) 2008-12-22 2016-04-14 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102008062825A1 (en) 2008-12-23 2010-06-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
FR2941951B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis 6- (6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
FR2941950B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
FR2941952B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis 6- (6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) DERIVATIVES 5-FLUORO-BENZOTHIAZOLES AND 5-FLUORO-BENZIMIDAZOLES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
FR2941949B1 (en) * 2009-02-06 2011-04-01 Sanofi Aventis DERIVATIVES OF 6- (6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
EP2406264A4 (en) * 2009-03-09 2012-08-08 Univ California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (en) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
CA2774715C (en) * 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CN102548995B (en) * 2009-08-12 2015-01-28 诺华股份有限公司 Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01453A (en) 2009-08-20 2015-06-05 Novartis Ag
CN102574853B (en) * 2009-08-20 2015-01-21 诺华股份有限公司 Heterocyclic oxime compounds
MX339811B (en) * 2009-09-16 2016-06-08 Celgene Avilomics Res Inc * Protein kinase conjugates and inhibitors.
WO2011061157A1 (en) * 2009-11-18 2011-05-26 Bayer Schering Pharma Aktiengesellschaft Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
TW201124078A (en) 2009-12-22 2011-07-16 Du Pont Fungicidal 2-(bicyclic aryloxy) carboxamides
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
EP2966075B1 (en) * 2009-12-31 2019-02-27 Hutchison Medipharma Limited Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
AR081039A1 (en) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc QUINASA FUSIONED BICYCLE INHIBITORS
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
EP2598505B1 (en) * 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
AR085183A1 (en) 2010-07-30 2013-09-18 Lilly Co Eli COMPOUND 6- (1-METHYL-1H-PIRAZOL-4-IL) -3- (2-METHYL-2H-INDAZOL-5-ILTIO) - [1,2,4] TRIAZOL [4,3-B] PIRIDAZINE, PHARMACEUTICAL COMPOSITION THAT UNDERSTAND AND USE IT TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT CANCER
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2536433T3 (en) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012087372A1 (en) 2010-12-22 2012-06-28 E. I. Du Pont De Nemours And Company Fungicidal 2-(bicyclic aryloxy)carboxamides
TW201242965A (en) 2011-02-01 2012-11-01 Kyowa Hakko Kirin Co Ltd Ring-fused heterocyclic derivative
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
EA028156B9 (en) 2011-05-10 2018-01-31 Джилид Сайэнс, Инк. Fused heterocyclic compounds as ion channel modulators
JP2014513724A (en) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー Fusion bicyclic kinase inhibitor
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NO3175985T3 (en) 2011-07-01 2018-04-28
TWI478908B (en) 2011-07-01 2015-04-01 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
ES2691650T3 (en) 2011-09-15 2018-11-28 Novartis Ag 3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met
CN103204844A (en) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 Amino heteroaryl compound, and preparation method and application thereof
CN103214481B (en) * 2012-01-21 2016-08-03 中国科学院上海药物研究所 Novel imidazole also [1,2-a] pyridine compounds and their, its preparation method, comprise the medical composition and its use of this compounds
EP2834246B1 (en) 2012-04-03 2021-07-28 Novartis AG Combination products with tyrosine kinase inhibitors and their use
CA2866321A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
CN106977495B (en) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 DNA-PK inhibitors
IN2014MN02562A (en) * 2012-06-27 2015-07-24 4Sc Discovery Gmbh
EA028722B1 (en) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Imidazopyridine derivatives as modulators of tnf activity
CN103122000B (en) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 High-selectivity c-Met kinase inhibitor used as antitumor drug
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
BR112015012454B1 (en) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated ATR KINASE INHIBITOR COMPOUNDS, THEIR USE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
ES2900061T3 (en) 2013-03-12 2022-03-15 Vertex Pharma DNA-PK inhibitors
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN105339368B (en) 2013-06-04 2017-08-15 拜耳制药股份公司 Imidazo [1,2 a] pyridine of 3 aryl substitution and application thereof
TWI636984B (en) 2013-06-24 2018-10-01 安美基公司 METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-a]PYRIDINES
CN104250257B (en) * 2013-06-25 2017-06-16 上海翰森生物医药科技有限公司 3,4 dihydro 1H benzos [c] [1,2] Evil boric acid compounds or its officinal salt and its production and use
CN104250252B (en) * 2013-06-28 2017-03-29 上海翰森生物医药科技有限公司 Pyrazolo [1,5 a] pyrimidines and preparation method thereof and medical usage
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
SG11201604519PA (en) 2013-12-06 2016-07-28 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
DK3096790T3 (en) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE
DK3431106T3 (en) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND USE OF THESE
KR102421235B1 (en) 2014-02-13 2022-07-15 인사이트 코포레이션 Cyclopropylamines as lsd1 inhibitors
EP3107920B1 (en) 2014-02-19 2017-10-18 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
JP2017508810A (en) 2014-03-21 2017-03-30 バイエル・ファルマ・アクティエンゲゼルシャフト Cyano-substituted imidazo [1,2-a] pyridinecarboxamide and uses thereof
KR20160142397A (en) * 2014-04-17 2016-12-12 암젠 인코포레이션 Polymorphic forms and co-crystals of a c-met inhibitor
CN105001242A (en) * 2014-04-23 2015-10-28 盛世泰科生物医药技术(苏州)有限公司 Heterocyclic compound as protein tyrosinase inhibitor
WO2015165930A1 (en) 2014-05-02 2015-11-05 Bayer Pharma Aktiengesellschaft Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
SI3145929T1 (en) 2014-05-23 2021-10-29 Hoffmann La Roche 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
EP3152212B9 (en) 2014-06-05 2020-05-27 Vertex Pharmaceuticals Inc. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
WO2015195740A1 (en) 2014-06-17 2015-12-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
AU2015342021B2 (en) 2014-11-03 2020-02-27 Bayer Pharma Aktiengesellschaft Piperidinylpyrazolopyrimidinones and their use
US10292970B2 (en) 2014-12-02 2019-05-21 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
HUE047382T2 (en) 2014-12-19 2020-04-28 Janssen Pharmaceutica Nv Heterocyclyl linked imidazopyridazine derivatives as pi3kbeta inhibitors
ME03517B (en) 2014-12-19 2020-04-20 Janssen Pharmaceutica Nv Imidazopyridazine derivatives as pi3kbeta inhibitors
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MY191796A (en) 2015-04-03 2022-07-15 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
WO2016208775A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
KR102665765B1 (en) 2015-07-20 2024-05-10 젠자임 코포레이션 Colony-stimulating factor-1 receptor (CSF-1R) inhibitors
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
US10501438B2 (en) 2015-08-11 2019-12-10 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
EP3334719B1 (en) 2015-08-12 2021-09-15 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
CN110402244B (en) 2015-08-12 2023-02-03 因赛特公司 Salts of LSD1 inhibitors
CN105272995B (en) * 2015-09-24 2017-10-27 上海海聚生物科技有限公司 Quinoline derivatives, its pharmaceutical composition, preparation method and application
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3366679B1 (en) 2015-10-20 2021-03-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
WO2017097671A1 (en) * 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
CN109414410B (en) 2016-04-22 2022-08-12 因赛特公司 Formulations of LSD1inhibitors
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN115819417A (en) 2016-09-09 2023-03-21 因赛特公司 Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
BR112019010880A2 (en) 2016-11-28 2019-10-01 Praxis Prec Medicines Inc compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018184976A1 (en) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyridinecarboxamides and use of same
SG11201909735YA (en) 2017-05-22 2019-11-28 Hoffmann La Roche Therapeutic compounds and compositions, and methods of use thereof
CN107200737B (en) * 2017-06-29 2019-03-26 武汉药明康德新药开发有限公司 Tertbutyloxycarbonyl -3- (methylol)-[1,2,3] triazole [1,5-a] piperidines -6- amide preparation method
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
WO2019136466A1 (en) 2018-01-08 2019-07-11 Yale University Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations
PL3755703T3 (en) 2018-02-20 2022-11-07 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
CN112423760A (en) 2018-05-30 2021-02-26 普拉克西斯精密药物股份有限公司 Ion channel modulators
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
CA3114462A1 (en) * 2018-10-17 2020-04-23 Duke University Quinone reductase 2 inhibitor compounds and uses thereof
KR20210106506A (en) 2018-12-21 2021-08-30 셀진 코포레이션 Thienopyridine inhibitor of RIPK2
US20200335182A1 (en) * 2019-04-16 2020-10-22 Uratim Ltd. Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
JP2022542392A (en) * 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Pyridine derivatives as KIF18A inhibitors
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
CN111187262A (en) * 2020-01-21 2020-05-22 沈阳药科大学 Imidazo [1,2-a ] pyridine derivative and preparation method and application thereof
CN111777549A (en) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 Synthesis process of 2-methoxy-3-bromo-5-fluoropyridine
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN113135913B (en) * 2021-04-28 2022-05-24 沈阳药科大学 3-substituent-6-pyridine substituent-six-membered and five-membered heterocyclic derivative and preparation method and application thereof
US20240158358A1 (en) * 2022-10-27 2024-05-16 Advancion Corporation Process for preparing 3-amino-1-butanol and related compounds

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
EP0156734A2 (en) * 1984-03-30 1985-10-02 Sanofi S.A. Triazolo[4,3-b]pyridazines, process for their preparation and pharmaceutical compositions containing them
EP0254623A1 (en) * 1986-07-23 1988-01-27 Laboratoires Upsa Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics
EP1481977A1 (en) * 2002-03-01 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound
WO2005010005A1 (en) * 2003-07-02 2005-02-03 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2006124692A2 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
WO2006124354A2 (en) * 2005-05-12 2006-11-23 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
WO2007075567A1 (en) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007138472A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260255A (en) * 1979-10-22 1981-04-07 The United States Of America As Represented By The Secretary Of The Army High energy laser beam sampling meter
US4260755A (en) * 1979-10-31 1981-04-07 American Cyanamid Company Novel 6-phenyl and substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines
US4405619A (en) 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
JPS60246387A (en) * 1984-05-22 1985-12-06 Yoshitomi Pharmaceut Ind Ltd Dihydroimidazo(1,2-a)pyrimidine derivative
JP2762522B2 (en) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 Angiogenesis inhibitor
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
NZ258697A (en) 1992-11-13 1996-03-26 Immunex Corp Elk-l polypeptide, coding sequence and vector therefor
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE4326758A1 (en) * 1993-08-10 1995-02-16 Basf Ag [1,3,4] triazolo [1,5-a] pyridines
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
FR2714907B1 (en) * 1994-01-07 1996-03-29 Union Pharma Scient Appl New adenosine derivatives, their preparation processes, pharmaceutical compositions containing them.
EP1464706A3 (en) 1994-04-15 2004-11-03 Amgen Inc., HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19534177A1 (en) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclic adhesion inhibitors
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO1999045009A1 (en) 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
DK2020408T3 (en) 1998-05-29 2013-09-30 Sugen Inc Pyrrole-substituted 2-indolinone as protein kinase inhibitor
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
JP2002520324A (en) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド Novel angiogenesis inhibitors
JP2002534468A (en) 1999-01-13 2002-10-15 バイエル コーポレイション ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors
DE60028740T2 (en) 1999-03-30 2007-05-24 Novartis Ag PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
JP4587626B2 (en) 1999-06-07 2010-11-24 イミュネックス・コーポレーション TEK antagonist
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
UA72946C2 (en) 1999-11-05 2005-05-16 Астразенека Аб Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf)
WO2001037820A2 (en) 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
JP2003523768A (en) 2000-02-25 2003-08-12 イミュネックス・コーポレーション Integrin antagonist
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
DE10038019A1 (en) * 2000-08-04 2002-02-14 Bayer Ag Substituted triazolopyride (az) ine
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
SI1343782T1 (en) 2000-12-21 2009-10-31 Smithkline Beecham Corp Pyrimidineamines as angiogenesis modulators
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP4385620B2 (en) * 2002-03-01 2009-12-16 アステラス製薬株式会社 Nitrogen-containing heterocyclic compounds
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2005002590A1 (en) 2003-07-01 2005-01-13 Astellas Pharma Inc. Agent inducing increase in bone mass
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
JP2004277337A (en) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
US7250212B2 (en) 2003-05-29 2007-07-31 Nichias Corporation Porous body-coated fiber, porous body-coated particle, and formed article using the same
US7250417B2 (en) * 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
JPWO2005077953A1 (en) 2004-02-18 2007-10-18 萬有製薬株式会社 Nitrogen-containing fused heteroaromatic ring derivatives
GB0403819D0 (en) * 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2573362A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BRPI0514391A (en) * 2004-08-18 2008-06-10 Pharmacia & Upjohn Co Llc triazolopyridine compounds for the treatment of inflammation
BE1016233A6 (en) * 2004-10-13 2006-05-02 Automatic limiter virgin and other vine climbing plants.
AU2005304784B2 (en) * 2004-11-04 2011-03-24 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
ES2330872T3 (en) * 2004-12-01 2009-12-16 Merck Serono Sa DERIVATIVES OF (1,2,4) TRIAZOLO (4,3-A) PIRIDINE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES.
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
KR20080026654A (en) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 Heterocyclic janus kinase 3 inhibitors
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
DE102005042742A1 (en) 2005-09-02 2007-03-08 Schering Ag Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
EP1845098A1 (en) 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
AU2007233709A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds
NL2000613C2 (en) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazole pyrazine derivatives.
PE20121506A1 (en) 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
EA016527B1 (en) 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Triazolopyridazine protein kinase modulators
US8629144B2 (en) 2007-06-21 2014-01-14 Janssen Pharmaceutica Nv Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
EP0156734A2 (en) * 1984-03-30 1985-10-02 Sanofi S.A. Triazolo[4,3-b]pyridazines, process for their preparation and pharmaceutical compositions containing them
EP0254623A1 (en) * 1986-07-23 1988-01-27 Laboratoires Upsa Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics
EP1481977A1 (en) * 2002-03-01 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Nitrogen-containing heterocyclic compound
WO2005010005A1 (en) * 2003-07-02 2005-02-03 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2006124354A2 (en) * 2005-05-12 2006-11-23 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2006124692A2 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
WO2007075567A1 (en) * 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
WO2007138472A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ABDEL-RAHMAN R M ET AL: "SYNTHESIS OF SOME NEW THIOETHERS OF 1,2,4-TRIAZINE-3-HYDRAZONES AND ASSAYS FOR THEIR ANTICANCER AND ANTI-HUMAN IMMUNE VIRUS ACTIVITIES", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 48, no. 3, 1 January 1993 (1993-01-01), pages 397 - 406, XP009066689, ISSN: 0014-827X *
ALBRIGHT J D ET AL: "Syntesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-tria zolo[4,3-b]pyridazines", JOURNAL OF MEDICINAL CHEMISTRY 1981 US, vol. 24, no. 5, 1981, pages 592 - 600, XP002508045, ISSN: 0022-2623 *
BRADY W T ET AL: "Intramolecular [2 + 2] ketene cycloadditions. Synthesis of isoflavones and 3-aroylbenzofurans", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON.; US, vol. 53, no. 7, 1 January 1988 (1988-01-01), pages 1353 - 1356, XP002339303, ISSN: 0022-3263 *
CADDICK S ET AL: "Observations on the intramolecular Heck reactions of aromatic chlorides using palladium/imidazolium salts", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 43, no. 51, 16 December 2002 (2002-12-16), pages 9347 - 9350, XP004392973, ISSN: 0040-4039 *
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 12 February 1993 (1993-02-12), XP002482346, Database accession no. 5619657 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 1966, XP002508050 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 1966, XP002508051 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1990, XP002508049, Database accession no. 1990:216834 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1996, XP002508048, Database accession no. 1996:576042 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1997, XP002508047, Database accession no. 1997:84644 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2006, XP002508046, Database accession no. 2006:594185 *
H.J.BERTHOLD, H.KNECHT: "Hochtemperaturammonolyse von Urantrichlorid und Urantetrachlorid", ANGEWANDTE CHEMIE, vol. 77, no. 9, 1965, pages 428 - 428, XP002508044 *
LABOUTA I M ET AL: "SYNTHESIS OF SOME SUBSTITUTED TRIAZOLO not 4,3-B 3/4 not 1,2,4 3/4 TRIAZINES AS POTENTIAL ANTICANCER AGENTS", MONATSHEFTE FUR CHEMIE, SPRINGER VERLAG. WIEN, AT, vol. 119, no. 5, 1 January 1988 (1988-01-01), pages 591 - 596, XP001053789, ISSN: 0026-9247 *
LOMBARDINO J G: "PREPARATION AND NEW REACTIONS OF IMIDAZO not 1,2-ALPHA 3/4 PYRIDINES", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, vol. 30, no. 7, 1 July 1965 (1965-07-01), pages 2403 - 2407, XP001055720, ISSN: 0022-3263 *
POTTS K T ET AL: "1,2,4-Triazoles.XII. Derivatives of the sigma-Triazolo[4,3-alpha]pyr idine Ring System", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, vol. 31, no. 1, 1 January 1966 (1966-01-01), pages 251 - 260, XP002369654, ISSN: 0022-3263 *
REIMLINGER H ET AL: "3-Benzoylamino-1,2,4-triazoles from N-Dichloromethylene-benzamide and Amidrazones", SYNTHESIS, 1970, pages 433 - 433, XP002482344 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399493B2 (en) 2004-09-17 2013-03-19 Janssen Pharmaceuticals, Inc. Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Also Published As

Publication number Publication date
AU2007272783A1 (en) 2008-01-17
CN101528743A (en) 2009-09-09
DK2081931T3 (en) 2016-12-19
BRPI0714387A2 (en) 2013-03-26
IL196243A (en) 2015-11-30
EP2081931B1 (en) 2016-08-31
NO20172002A1 (en) 2009-02-13
MY167135A (en) 2018-08-13
NZ574002A (en) 2012-05-25
ES2592888T3 (en) 2016-12-02
US20090124612A1 (en) 2009-05-14
TWI394755B (en) 2013-05-01
EP2578583A1 (en) 2013-04-10
KR20090029843A (en) 2009-03-23
IL196243A0 (en) 2009-09-22
EA200900178A1 (en) 2009-06-30
MX2009000531A (en) 2009-05-08
KR20120039756A (en) 2012-04-25
AU2007272783A8 (en) 2009-02-05
AR062056A1 (en) 2008-10-15
EA016028B1 (en) 2012-01-30
CN101528743B (en) 2013-02-06
AU2007272783B2 (en) 2012-04-26
EP3093289A1 (en) 2016-11-16
CA2657327A1 (en) 2008-01-17
ZA200900662B (en) 2010-03-31
PE20080403A1 (en) 2008-04-25
US8212041B2 (en) 2012-07-03
UA95965C2 (en) 2011-09-26
JP2009543789A (en) 2009-12-10
KR101140474B1 (en) 2012-05-08
CR10614A (en) 2009-03-23
CL2007002062A1 (en) 2008-01-18
WO2008008539A2 (en) 2008-01-17
TW200817396A (en) 2008-04-16
PE20121506A1 (en) 2012-11-26
NO20090723L (en) 2009-02-13
EP2081931A2 (en) 2009-07-29
JP5532398B2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
WO2008008539A3 (en) Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
HK1116161A1 (en) Substituted amide derivatives as protein kinase inhibitors
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
WO2008079291A3 (en) Substituted heterocycles and methods of use
EA200601350A1 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATIONS
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
MX2009008531A (en) Nitrogen-containing heterocyclyl ketones and methods of use.
MX2009006543A (en) Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer.
WO2005073224A3 (en) Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
ATE404552T1 (en) SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
ATE517882T1 (en) QUINOLINE DERIVATIVES
DE602004024900D1 (en) SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHOD OF USE
WO2009155121A3 (en) Inhibitors of pi3 kinase
ATE440834T1 (en) SUBSTITUTED ARYLAMIN DERIVATIVES AND METHODS OF USE
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
EA201070929A1 (en) FURO-THYENO [3,2-c] Pyridine
WO2011051490A3 (en) Heterocyclic derivatives
GEP20135806B (en) Lactams as beta secretase inhibitors
ATE540038T1 (en) HETEROCYCLES AS PROTEIN KINASE INHIBITORS
MX2007000576A (en) Nicotinic receptor agonists for the treatment of inflammatory diseases.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780034205.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810473

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 196243

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007272783

Country of ref document: AU

Ref document number: 574002

Country of ref document: NZ

Ref document number: 81/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2657327

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009519563

Country of ref document: JP

Ref document number: 2009010058

Country of ref document: EG

Ref document number: 12009500115

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/000531

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007272783

Country of ref document: AU

Date of ref document: 20070713

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200900178

Country of ref document: EA

REEP Request for entry into the european phase

Ref document number: 2007810473

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2009-010614

Country of ref document: CR

Ref document number: 2007810473

Country of ref document: EP

Ref document number: 1020097003060

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020127005840

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0714387

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090113